Mulder K - Search Results

1

¹⁸F-Fluorodeoxyglucose Positron Emission Tomography Parameters can Predict Long-Term Outcome Following Trimodality Treatment for Oesophageal Cancer.

Abraham AG, Riauka T, Hudson M, Ghosh S, Zebak S, Alba V, Vaihenberg E, Warkentin H, Tankel K, Severin D, Bedard E, Spratlin J, Mulder K, Joseph K. Abraham AG, et al. Among authors: mulder k. Clin Oncol (R Coll Radiol). 2023 Mar;35(3):177-187. doi: 10.1016/j.clon.2022.11.003. Epub 2022 Nov 16. Clin Oncol (R Coll Radiol). 2023. PMID: 36402622

2

Ramucirumab (IMC-1121B): a novel attack on angiogenesis.

Spratlin JL, Mulder KE, Mackey JR. Spratlin JL, et al. Future Oncol. 2010 Jul;6(7):1085-94. doi: 10.2217/fon.10.75. Future Oncol. 2010. PMID: 20624120

3

The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.

Mulder K, Scarfe A, Chua N, Spratlin J. Mulder K, et al. Expert Opin Biol Ther. 2011 Mar;11(3):405-13. doi: 10.1517/14712598.2011.557657. Epub 2011 Feb 1. Expert Opin Biol Ther. 2011. PMID: 21281258 Review.

4

Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future.

Mulder K, Koski S, Scarfe A, Chu Q, King K, Spratlin J. Mulder K, et al. Oncotarget. 2010 Nov;1(7):515-529. doi: 10.18632/oncotarget.187. Oncotarget. 2010. PMID: 21317448 Free PMC article. Review.

5

Targeting metastatic upper gastrointestinal adenocarcinomas.

Spratlin JL, Chu Q, Koski S, King K, Mulder K. Spratlin JL, et al. Among authors: mulder k. World J Clin Oncol. 2011 Mar 10;2(3):135-49. doi: 10.5306/wjco.v2.i3.135. World J Clin Oncol. 2011. PMID: 21611088 Free PMC article.

6

Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.

Spratlin JL, Mulder KE. Spratlin JL, et al. Int J Mol Sci. 2011;12(9):5895-907. doi: 10.3390/ijms12095895. Epub 2011 Sep 14. Int J Mol Sci. 2011. PMID: 22016635 Free PMC article. Review.

7

Impact of a dedicated cancer center surveillance program on guideline adherence for patients with stage II and III colorectal cancer.

Standeven L, Price Hiller J, Mulder K, Zhu G, Ghosh S, Spratlin JL. Standeven L, et al. Among authors: mulder k. Clin Colorectal Cancer. 2013 Jun;12(2):103-12. doi: 10.1016/j.clcc.2012.09.006. Epub 2012 Nov 13. Clin Colorectal Cancer. 2013. PMID: 23153862

8

Clinicopathologic characteristics and survival outcomes of patients with advanced esophageal, gastroesophageal junction, and gastric adenocarcinoma: a single-institution experience.

Dechaphunkul A, Mulder K, El-Gehani F, Ghosh S, Deschenes J, Spratlin J. Dechaphunkul A, et al. Among authors: mulder k. Curr Oncol. 2012 Dec;19(6):302-7. doi: 10.3747/co.19.1081. Curr Oncol. 2012. PMID: 23300355 Free PMC article.

9

Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer.

Loree JM, Mulder KE, Ghosh S, Spratlin JL. Loree JM, et al. J Gastrointest Cancer. 2014 Jun;45(2):154-60. doi: 10.1007/s12029-013-9574-7. J Gastrointest Cancer. 2014. PMID: 24408272

10

CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.

Loree JM, Mulder KE, Ghosh S, Spratlin JL. Loree JM, et al. Clin Colorectal Cancer. 2014 Sep;13(3):172-7. doi: 10.1016/j.clcc.2014.01.001. Epub 2014 Feb 6. Clin Colorectal Cancer. 2014. PMID: 24630275

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

319 results

Search Page

Filters